{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:40:04Z","timestamp":1791189604867,"version":"4.1.0"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Dutch Ministry of Economic Affairs"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.antiviral.2014.03.008","type":"journal-article","created":{"date-parts":[[2014,3,26]],"date-time":"2014-03-26T01:22:24Z","timestamp":1395796944000},"page":"24-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["One Health approach to Rift Valley fever vaccine development"],"prefix":"10.1016","volume":"106","author":[{"given":"Jeroen","family":"Kortekaas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.03.008_b0005","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1086\/345671","article-title":"Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans","volume":"36","author":"Al-Hazmi","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.03.008_b0010","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3201\/eid1606.091266","article-title":"Rift Valley fever during rainy seasons, Madagascar, 2008 and 2009","volume":"16","author":"Andriamandimby","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.03.008_b0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4269\/ajtmh.2010.09-0289","article-title":"Prediction, assessment of the Rift Valley fever activity in East and Southern Africa 2006\u20132008 and possible vector control strategies","volume":"83","author":"Anyamba","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2014.03.008_b0020","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3201\/eid1902.120834","article-title":"Rift Valley fever, Sudan, 2007 and 2010","volume":"19","author":"Aradaib","year":"2013","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.03.008_b0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7196\/SAMJ.4544","article-title":"Outbreak of Rift Valley fever affecting veterinarians and farmers in South Africa, 2008","volume":"101","author":"Archer","year":"2011","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.antiviral.2014.03.008_b0030","doi-asserted-by":"crossref","first-page":"e725","DOI":"10.1371\/journal.pntd.0000725","article-title":"Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus","volume":"4","author":"Bhardwaj","year":"2010","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.antiviral.2014.03.008_b0035","first-page":"160","article-title":"Immunization against Rift Valley fever. The development of vaccines from nonprimate cell cultures and chick embryos","volume":"77","author":"Binn","year":"1963","journal-title":"Am. J. Hyg."},{"key":"10.1016\/j.antiviral.2014.03.008_b0040","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1128\/JVI.02501-07","article-title":"Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals","volume":"82","author":"Bird","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.virol.2007.01.046","article-title":"Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease","volume":"362","author":"Bird","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.03.008_b0050","doi-asserted-by":"crossref","first-page":"12901","DOI":"10.1128\/JVI.06046-11","article-title":"Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep","volume":"85","author":"Bird","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0055","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.coviro.2012.02.017","article-title":"Breaking the chain: Rift Valley fever virus control via livestock vaccination","volume":"2","author":"Bird","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0060","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1016\/j.vaccine.2011.04.043","article-title":"A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(\u2212\/\u2212) mice upon lethal virus challenge","volume":"29","author":"Boshra","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2009.08.002","article-title":"Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines","volume":"84","author":"Bouloy","year":"2009","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.03.008_b0070","doi-asserted-by":"crossref","first-page":"10310","DOI":"10.1128\/JVI.05252-11","article-title":"Creation of a recombinant Rift Valley fever virus with a two-segmented genome","volume":"85","author":"Brennan","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0075","first-page":"46","article-title":"Newcastle disease virus as a vaccine vector for humans","volume":"10","author":"Bukreyev","year":"2008","journal-title":"Curr. Opin. Mol. Ther."},{"issue":"Pt. 10","key":"10.1016\/j.antiviral.2014.03.008_b0080","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development","volume":"66","author":"Caplen","year":"1985","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0085","unstructured":"CDC, 1998. Rift Valley Fever \u2013 East Africa, 1997\u20131998. MMWR. Morbidity and mortality weekly report 47, pp. 261\u20134."},{"key":"10.1016\/j.antiviral.2014.03.008_b0090","unstructured":"CDC, 2000a. Outbreak of Rift Valley fever \u2013 Saudi Arabia, August-October, 2000. MMWR. Morbidity and mortality weekly report 49, pp. 905\u2013908."},{"key":"10.1016\/j.antiviral.2014.03.008_b0095","unstructured":"CDC, 2000b. Outbreak of Rift Valley fever \u2013 Yemen, August-October 2000. MMWR. Morbidity and mortality weekly report 49, pp. 1065, 1066."},{"key":"10.1016\/j.antiviral.2014.03.008_b0100","unstructured":"CDC, 2000c. Update: outbreak of Rift Valley Fever \u2013 Saudi Arabia, August\u2013November 2000. MMWR. Morbidity and mortality weekly report 49, pp. 982\u2013985."},{"key":"10.1016\/j.antiviral.2014.03.008_b0105","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(00)99645-4","article-title":"Rift Valley fever","volume":"218","author":"Daubney","year":"1931","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2014.03.008_b0110","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/path.1700340418","article-title":"Enzootic hepatitis or rift valley fever. An undescribed virus disease of sheep cattle and man from East Africa","volume":"34","author":"Daubney","year":"1931","journal-title":"J. Pathol. Bacteriol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0115","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/path.1700340418","article-title":"Enzootic hepatitis or Rift Valley fever: an undescribed disease of sheep, cattle and man from East Africa","volume":"34","author":"Daubney","year":"1931","journal-title":"J. Pathol. Bacteriol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0120","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.vaccine.2009.12.062","article-title":"Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge","volume":"28","author":"de Boer","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0125","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1128\/JVI.07104-11","article-title":"Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge","volume":"86","author":"Dodd","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0130","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1016\/j.vaccine.2010.04.085","article-title":"Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep","volume":"28","author":"Dungu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0135","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3201\/eid1710.110397","article-title":"Unexpected Rift Valley fever outbreak, northern Mauritania","volume":"17","author":"El Mamy","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.03.008_b0140","unstructured":"FDA, 2013. Approval of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible Code of Federal Regulations."},{"key":"10.1016\/j.antiviral.2014.03.008_b0145","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0035-9203(32)90042-X","article-title":"Rift Valley fever or enzootic hepatitis","volume":"25","author":"Findlay","year":"1932","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2014.03.008_b0150","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0140-6736(00)99624-7","article-title":"The virus of Rift Valley fever or enzootic hepatitis","volume":"221","author":"Findlay","year":"1931","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2014.03.008_b0155","first-page":"930","article-title":"Rift valley fever in man, complicated by retinal changes and loss of vision","volume":"25","author":"Freed","year":"1951","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.antiviral.2014.03.008_b0160","first-page":"908","article-title":"Rift valley fever in South Africa. 2. The occurrence of human cases in the Orange Free State, the North-Western Cape Province, the Western and Southern Transvaal. B. Field and Laboratory Investigation","volume":"25","author":"Gear","year":"1951","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.antiviral.2014.03.008_b0165","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.virol.2006.09.035","article-title":"The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection","volume":"359","author":"Gerrard","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.03.008_b0170","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virol.2007.04.014","article-title":"Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins","volume":"366","author":"Gorchakov","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.03.008_b0175","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1128\/JVI.02341-13","article-title":"Aerosolized Rift Valley Fever virus causes fatal encephalitis in African green monkeys and common marmosets","volume":"88","author":"Hartman","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0180","doi-asserted-by":"crossref","first-page":"e1229","DOI":"10.1371\/journal.pntd.0001229","article-title":"The 2007 Rift Valley fever outbreak in Sudan","volume":"5","author":"Hassan","year":"2011","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.antiviral.2014.03.008_b0185","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1017\/S0950268808001696","article-title":"An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus","volume":"137","author":"Heise","year":"2009","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.antiviral.2014.03.008_b0190","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1128\/CVI.00182-09","article-title":"A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity","volume":"16","author":"Holman","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0195","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/0035-9203(79)90005-1","article-title":"The Rift Valley fever epizootic in Egypt 1977\u201378. 2. Ecological and entomological studies","volume":"73","author":"Hoogstraal","year":"1979","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2014.03.008_b0200","first-page":"95","article-title":"Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep","volume":"69","author":"Hunter","year":"2002","journal-title":"Onderstepoort J. Vet. Res."},{"key":"10.1016\/j.antiviral.2014.03.008_b0205","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0923-2516(89)80096-2","article-title":"Analytical study of a Rift Valley fever epidemic","volume":"140","author":"Jouan","year":"1989","journal-title":"Res. Virol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0210","first-page":"307","article-title":"An RVF epidemic in southern Mauritania. Annales de l\u2019Institut Pasteur","volume":"139","author":"Jouan","year":"1988","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.03.008_b0215","first-page":"890","article-title":"Rift Valley fever in South Africa: 2. The occurrence of human cases in the Orange Free State, the north-western Cape province, the western and southern Transvaal. A epidemiological and clinical findings","volume":"25","author":"Joubert","year":"1951","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.antiviral.2014.03.008_b0220","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2915.2002.00371.x","article-title":"The 2000 epidemic of Rift Valley fever in Saudi Arabia: mosquito vector studies","volume":"16","author":"Jupp","year":"2002","journal-title":"Med. Vet. Entomol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0225","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0042-6822(89)90442-X","article-title":"Rift Valley fever virus M segment: phlebovirus expression strategy and protein glycosylation","volume":"170","author":"Kakach","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.03.008_b0230","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/JVI.62.3.826-833.1988","article-title":"Rift Valley fever virus M segment: use of recombinant vaccinia viruses to study Phlebovirus gene expression","volume":"62","author":"Kakach","year":"1988","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0235","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/oxfordjournals.aje.a113471","article-title":"A Rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up","volume":"116","author":"Kark","year":"1982","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0240","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0264-410X(85)90060-X","article-title":"A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison of intradermal versus subcutaneous injection","volume":"3","author":"Kark","year":"1985","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0245","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4269\/ajtmh.1934.s1-14.547","article-title":"Laboratory infections with the virus of Rift Valley fever","volume":"14","author":"Kitchen","year":"1934","journal-title":"Am. J. Trop. Med."},{"key":"10.1016\/j.antiviral.2014.03.008_b0250","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1016\/j.vaccine.2012.03.027","article-title":"Efficacy of three candidate Rift Valley fever vaccines in sheep","volume":"30","author":"Kortekaas","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0255","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1016\/j.vaccine.2010.04.048","article-title":"Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector","volume":"28","author":"Kortekaas","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0260","doi-asserted-by":"crossref","first-page":"12622","DOI":"10.1128\/JVI.00841-11","article-title":"Creation of a nonspreading Rift Valley fever virus","volume":"85","author":"Kortekaas","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0265","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3201\/eid1709.110506","article-title":"Rift Valley fever vaccine development, progress and constraints","volume":"17","author":"Kortekaas","year":"2011","journal-title":"Emerg. Infect. Dis."},{"issue":"Suppl. 2","key":"10.1016\/j.antiviral.2014.03.008_b0270","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1863-2378.2012.01478.x","article-title":"Virus-like particle-based countermeasures against Rift Valley fever virus","volume":"59","author":"Koukuntla","year":"2012","journal-title":"Zoonoses Public Health"},{"key":"10.1016\/j.antiviral.2014.03.008_b0275","doi-asserted-by":"crossref","first-page":"e1265","DOI":"10.1371\/journal.pntd.0001265","article-title":"Postepidemic analysis of Rift Valley fever virus transmission in northeastern kenya: a village cohort study","volume":"5","author":"LaBeaud","year":"2011","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.antiviral.2014.03.008_b0280","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1743-422X-6-6","article-title":"Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs","volume":"6","author":"Lagerqvist","year":"2009","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2014.03.008_b0285","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jbiotec.2012.08.012","article-title":"The future of human DNA vaccines","volume":"162","author":"Li","year":"2012","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0290","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1371\/journal.pntd.0002309","article-title":"A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection","volume":"7","author":"Lopez-Gil","year":"2013","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.antiviral.2014.03.008_b0295","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/j.vaccine.2010.02.018","article-title":"Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(\u2212\/\u2212) mice induced by different DNA vaccination regimens","volume":"28","author":"Lorenzo","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0300","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1016\/j.vaccine.2008.07.042","article-title":"Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep","volume":"26","author":"Lorenzo","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0305","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1086\/378747","article-title":"Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics","volume":"37","author":"Madani","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.03.008_b0310","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.virol.2009.11.001","article-title":"A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge","volume":"397","author":"Mandell","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.03.008_b0315","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jviromet.2010.07.015","article-title":"Novel suspension cell-based vaccine production systems for Rift Valley fever virus-like particles","volume":"169","author":"Mandell","year":"2010","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.antiviral.2014.03.008_b0320","first-page":"803","article-title":"Rift Valley fever in humans in South Africa","volume":"58","author":"McIntosh","year":"1980","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.antiviral.2014.03.008_b0325","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0035-9203(79)90004-X","article-title":"The Rift Valley fever epizootic in Egypt 1977\u201378. 1. Description of the epizootic and virological studies","volume":"73","author":"Meegan","year":"1979","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2014.03.008_b0330","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/vr.105.6.124","article-title":"An epizootic of Rift Valley fever in Egypt in 1977","volume":"105","author":"Meegan","year":"1979","journal-title":"Vet. Rec."},{"key":"10.1016\/j.antiviral.2014.03.008_b0335","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.4269\/ajtmh.1980.29.1405","article-title":"Experimental transmission and field isolation studies implicating Culex pipiens as a vector of Rift Valley fever virus in Egypt","volume":"29","author":"Meegan","year":"1980","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2014.03.008_b0340","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3201\/eid0812.020194","article-title":"Isolation and genetic characterization of Rift Valley fever virus from Aedes vexans arabiensis, Kingdom of Saudi Arabia","volume":"8","author":"Miller","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.03.008_b0345","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4269\/ajtmh.2010.09-0318","article-title":"Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in Tanzania, 2007","volume":"83","author":"Mohamed","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2014.03.008_b0350","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0264-410X(91)90314-V","article-title":"Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep","volume":"9","author":"Morrill","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0355","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2460\/ajvr.1987.48.07.1042","article-title":"Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes","volume":"48","author":"Morrill","year":"1987","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.antiviral.2014.03.008_b0360","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2012.10.118","article-title":"Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0365","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2460\/ajvr.1997.58.10.1104","article-title":"Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle","volume":"58","author":"Morrill","year":"1997","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.antiviral.2014.03.008_b0370","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2460\/ajvr.1997.58.10.1110","article-title":"Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids","volume":"58","author":"Morrill","year":"1997","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.antiviral.2014.03.008_b0375","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1016\/S0264-410X(03)00131-2","article-title":"Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys","volume":"21","author":"Morrill","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0380","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/infdis\/jir354","article-title":"Mucosal immunization of rhesus macaques with Rift Valley Fever MP-12 vaccine","volume":"204","author":"Morrill","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.03.008_b0385","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/infdis\/jir249","article-title":"Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent rift valley fever virus","volume":"204","author":"Morrill","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.03.008_b0390","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.1995.53.405","article-title":"Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment","volume":"53","author":"Muller","year":"1995","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2014.03.008_b0395","first-page":"797","article-title":"Rift valley fever; I. The occurrence of human cases in Johannesburg","volume":"25","author":"Mundel","year":"1951","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.antiviral.2014.03.008_b0400","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.3201\/eid0706.010627","article-title":"Rift Valley fever outbreak, Mauritania, 1998: seroepidemiologic, virologic, entomologic, and zoologic investigations","volume":"7","author":"Nabeth","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.03.008_b0405","doi-asserted-by":"crossref","first-page":"e77461","DOI":"10.1371\/journal.pone.0077461","article-title":"A single vaccination with an improved nonspreading Rift Valley fever virus vaccine provides sterile immunity in lambs","volume":"8","author":"Oreshkova","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2014.03.008_b0410","doi-asserted-by":"crossref","first-page":"14926","DOI":"10.1073\/pnas.1112149108","article-title":"Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice","volume":"108","author":"Papin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2014.03.008_b0415","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01311021","article-title":"Experimental Rift Valley fever in rhesus macaques","volume":"99","author":"Peters","year":"1988","journal-title":"Arch. Virol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0420","series-title":"Rift Valley Fever, Handbook of Zoonoses","author":"Peters","year":"1994"},{"key":"10.1016\/j.antiviral.2014.03.008_b0425","series-title":"Genetic and Clinical Evaluation of MP-12: A Live Attenuated Vaccine for Rift Valley Fever Virus (RVFV)","author":"Peters","year":"2008"},{"key":"10.1016\/j.antiviral.2014.03.008_b0430","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4049\/jimmunol.93.2.293","article-title":"Immunization against Rift Valley fever virus. Studies on the immunogenicity of lyophilized formalin-inactivated vaccine","volume":"93","author":"Randall","year":"1964","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0435","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4049\/jimmunol.89.5.660","article-title":"The development of a formalin-killed Rift Valley fever virus vaccine for use in man","volume":"89","author":"Randall","year":"1962","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0440","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1016\/j.vaccine.2011.02.037","article-title":"Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study","volume":"29","author":"Rusnak","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0445","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0264-410X(90)90096-5","article-title":"Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine","volume":"8","author":"Saluzzo","year":"1990","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0450","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0042-6822(89)90365-6","article-title":"Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins","volume":"170","author":"Schmaljohn","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.03.008_b0455","first-page":"926","article-title":"Macular changes in rift valley fever","volume":"25","author":"Schrire","year":"1951","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.antiviral.2014.03.008_b0460","unstructured":"Schulz, K.H., 1951. Rift Valley fever in South Africa, Special Report No. 5\/51 Union Department of Health, Plague Research Laboratory, pp. 1\u201326."},{"key":"10.1016\/j.antiviral.2014.03.008_b0465","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1084\/jem.59.3.305","article-title":"Rift Valley fever in man: report of a fatal laboratory infection complicated by thrombophlebitis","volume":"59","author":"Schwentker","year":"1934","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2014.03.008_b0470","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/JVI.06190-11","article-title":"Development of a novel nonhuman primate model for Rift Valley fever","volume":"86","author":"Smith","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0475","first-page":"107","article-title":"Rift Valley fever; isolation of the virus from wild mosquitoes","volume":"29","author":"Smithburn","year":"1948","journal-title":"Br. J. Exp. Pathol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0480","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4049\/jimmunol.62.2.213","article-title":"Rift Valley fever; accidental infections among laboratory workers","volume":"62","author":"Smithburn","year":"1949","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0485","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1016\/j.vaccine.2005.08.034","article-title":"Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus","volume":"24","author":"Spik","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0490","first-page":"867","article-title":"Rift Valley fever affecting humans in South Africa: a clinicopathological study","volume":"51","author":"van Velden","year":"1977","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.antiviral.2014.03.008_b0495","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1128\/JVI.74.3.1538-1543.2000","article-title":"The S segment of rift valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice","volume":"74","author":"Vialat","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.03.008_b0500","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-1702(97)00097-X","article-title":"Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation","volume":"52","author":"Vialat","year":"1997","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2014.03.008_b0505","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1016\/j.vaccine.2011.05.055","article-title":"Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves","volume":"29","author":"von Teichman","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0510","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1016\/j.vaccine.2006.06.041","article-title":"Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever","volume":"24","author":"Wallace","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0515","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/1743-422X-10-349","article-title":"Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice","volume":"10","author":"Warimwe","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2014.03.008_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2013.12.064","article-title":"Efficacy of a recombinant Rift Valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep","author":"Weingartl","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.03.008_b0525","unstructured":"WHO, 2000. Outbreak of Rift Valley fever, Yemen, August\u2013October 2000. Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations=Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations 75, pp. 392\u2013395."},{"key":"10.1016\/j.antiviral.2014.03.008_b0530","unstructured":"WHO, 2010. Rift Valley fever, South Africa \u2013 update. Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations=Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations 85, pp. 185, 186."},{"key":"10.1016\/j.antiviral.2014.03.008_b0535","unstructured":"WHO, 2012. Outbreak news. Rift Valley fever, Mauritania. Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations=Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations 87, p. 438."},{"key":"10.1016\/j.antiviral.2014.03.008_b0540","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3201\/eid0802.010023","article-title":"An outbreak of Rift Valley fever in Northeastern Kenya, 1997\u201398","volume":"8","author":"Woods","year":"2002","journal-title":"Emerg. Infect. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214000825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214000825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:48:33Z","timestamp":1746146913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354214000825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":108,"alternative-id":["S0166354214000825"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.03.008","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One Health approach to Rift Valley fever vaccine development","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}